| Company Name: |
ChemStrong Scientific Co.,Ltd
|
| Tel: |
0755-0755-66853366 13670046396 |
| Email: |
sales@chem-strong.com |
| Products Intro: |
Product Name:DBIBB
CAS:1569309-92-7
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:DBIBB
CAS:1569309-92-7
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:DBIBB
CAS:1569309-92-7
Purity:NULL Package:10mg;1mg;5mg Remarks:NULL
|
|
| Product Name: | DBIBB | | Synonyms: | DBIBB;Benzoic acid, 2-[[[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]amino]sulfonyl]- | | CAS: | 1569309-92-7 | | MF: | C23H20N2O6S | | MW: | 452.48 | | EINECS: | | | Product Categories: | | | Mol File: | 1569309-92-7.mol |  |
| | DBIBB Chemical Properties |
| Boiling point | 710.4±70.0 °C(Predicted) | | density | 1.437±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≤30mg/ml in DMSO;10mg/ml in dimethyl formamide | | form | crystalline solid | | pka | 3.02±0.36(Predicted) |
| | DBIBB Usage And Synthesis |
| Uses | DBIBB is a non-lipid agonist of LPA2 (lysophosphatidic acid receptor 2), protecting rat intestinal crpyt epithelium-like IEC-6 cells against caspase 3/7 activation and apoptosis. | | Biological Activity | dbibb, a butylsulfamoyl benzoic acid analog, is a non-lipid agonist of lpa2 with an ec50 of 0.10 μm. dbibb has no effect at other lpa receptor subtypes [1]. the bioactive phospholipid lysophosphatidic acid (lpa) has been involved in stimulating cell proliferation, migration and survival by acting on its cognate g-protein-coupled receptors. aberrant lpa production, receptor expression and signalling probably contribute to cancer initiation, progression and metastasis [2]. | | in vitro | dbibb treatment postirradiation significantly (p< 0.01) increased the clonogenic survival of iec-6 cells in the 2-6 gy dose range. dbibb reduced dna fragmentation 4hr after irradiation in a dose dependent manner. dbibb also reduced caspase 3/7 activity and dna fragmentation in lpa2mef treated with adriamycin. in purified cd34+ progenitor cells, dbibb significantly increased the total number of colonies and specifically enhanced the survival of the granulocyte/macrophage lineages [1]. | | in vivo | using a murine gi-ars mice model of partial-body irradiation (pbi) with shielding of the bone marrow contained in the tibiae, fibulae, and paws, administrations of up to 10 mg/kg of dbibb for 10 days showed no visually observable adverse effects and pathological findings at necropsy, indicating the lack of toxicity. the group that received 10 mg/kg dbibb showed a significant increase in survival. in c57bl/6 mice, dbibb showed a dose-dependent increase in the number of surviving crypts compared with the vehicle control [1]. | | references | [1] patil r, szabó e, fells j i, et al. combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an lpa 2 receptor-specific nonlipid agonist[j]. chemistry & biology, 2015, 22(2): 206-216.
[2] mills g b, moolenaar w h. the emerging role of lysophosphatidic acid in cancer[j]. nature reviews cancer, 2003, 3(8): 582-591. |
| | DBIBB Preparation Products And Raw materials |
|